CN103989648A - Lomoxicam dispersible tablet and preparation method thereof - Google Patents
Lomoxicam dispersible tablet and preparation method thereof Download PDFInfo
- Publication number
- CN103989648A CN103989648A CN201410239718.6A CN201410239718A CN103989648A CN 103989648 A CN103989648 A CN 103989648A CN 201410239718 A CN201410239718 A CN 201410239718A CN 103989648 A CN103989648 A CN 103989648A
- Authority
- CN
- China
- Prior art keywords
- acid
- chlorine
- promise
- chlorine promise
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a lomoxicam dispersible tablet, a preparation method and application thereof. The lomoxicam dispersible tablet is prepared from the following components in percentage by weight: 0.5-16 percent of lomoxicam, 10-50 percent of filler, 10-50 percent of disintegrating agent, 10-60 percent of an acidifying agent, 0.1-20 percent of adhesive and 0.1-30 percent of lubricant and flow aid. Compared with a common tablet, the dispersible tablet has the advantages of no surfacant, excellent solubility, dispersibility and disintegrating property, and complete integration in 1 minute. The lomoxicam dispersible tablet prepared by the method is high in solubility, good in bioavailability, stable in quality and good in flavor, and can be quickly distributed in a body; the preparation method is simple and practical, and is applicable to industrial production.
Description
Invention field
The present invention relates to chemical pharmacy field, be specifically related to a kind of chlorine promise for healthy dispersion tablet and preparation method thereof.
Background of invention
Lornoxicam (Lomoxicam), chemical name is 6-chloro-4-hydroxyl-2-methyl-3-(2-pyridine carbamoyl)-2H-thieno [2,3-e]-l, 2-thiazine-1,1-dioxide, belongs to oxygen former times health non-steroid anti-inflammation analgesia medicine.It has stronger analgesia and antiinflammatory action, in can be used for that surgical postoperative acute pain, wound cause, to severe pain, acute sciatica and lumbago, various headache, ache in late cancer, also can be used for the treatment of chronic back pain, osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
Lornoxicam parenteral administration is equally effective with morphine, pethidine and tramadol aspect alleviation postoperative pain, but the toleration of lornoxicam is better than morphine and tramadol.Cancer pain patient, lornoxicam can also reduce the consumption of morphine as auxiliary analgesic.Document also shows, in the time of 10 multiple dose of antiinflammatory dosage, lornoxicam also can produce refrigeration function.
Chinese patent CN200410053987 discloses a kind of oral rapidly disintegrating compositions, and said preparation comprises lipid odor mask and disintegrating agent.Chinese patent CN200610118425 discloses a kind of chlorine promise for health slow releasing tablet and preparation method thereof, comprises one or more adjuvants.But it is the lornoxicam dispersible tablet of unexposed pharmaceutical preparation formula of the present invention.
Existing market sell is into chlorine promise is for health conventional tablet or dispersible tablet, but unexposed drug component ratio of the present invention, do not adopt acidulant yet, chlorine promise provided by the invention adopts acidulant by its parcel or wraps up mutually for healthy dispersion tablet, thereby reach the effect of embedding, disintegration rate is fast, has also improved its bioavailability simultaneously.
Summary of the invention
The invention provides a kind of chlorine promise for healthy dispersion tablet, be to replace health pharmaceutical dosage forms or add surfactant according to existing chlorine promise body is had to the problems such as stimulation and bioavailability are not high, or do not adopt acidulant.The invention provides a kind of chlorine promise for healthy dispersion tablet, adopt acidulant by its parcel or parcel mutually, thereby reach the effect of embedding, and through repetition test by each component screening to weight ratio of the present invention, be surprised to find that the dispersible tablet steady quality obtaining, stripping is fast, in body, distributes rapidly, and bioavailability is high, dispersibility, disintegrative are good, can disintegrate in 1 minute complete, and this product is containing surfactant, and can reduce stimulates body.
On the one hand, the invention provides a kind of chlorine promise for healthy dispersion tablet, it comprises as follows according to the component of percetage by weight meter: chlorine promise is for health 0.5～16%, filler 10～50%, disintegrating agent 10～50%, acidulant 10～60%, binding agent 0.1～20%, lubricant and fluidizer 0.1～30%.
Some embodiments therein, chlorine promise of the present invention is for healthy dispersion tablet, and it comprises as follows according to the component of percetage by weight meter: chlorine promise is for health 8%, filler 40%, disintegrating agent 37%, acidulant 10%, binding agent 2%, lubricant and fluidizer 3%.
In other embodiments, chlorine promise of the present invention is for healthy dispersion tablet, and it comprises the component by following percetage by weight:
Chlorine promise is for health 8g
Lactose 300g
Crospolyvinylpyrrolidone 67g
Carboxymethylstach sodium 200g
Hydroxypropyl methylcellulose 3.5g
Citric acid 100g
Micropowder silica gel 25g
Magnesium stearate 7.5g
Water 175
95% ethanol 114g
Make 1000.
Some embodiments therein, chlorine promise of the present invention is for healthy dispersion tablet, and wherein, described filler is a kind of in starch, Icing Sugar, dextrin, lactose, microcrystalline Cellulose, mannitol, sorbitol or xylitol or their mixture.
Some embodiments therein, chlorine promise of the present invention is for healthy dispersion tablet, wherein, described disintegrating agent is a kind of in microcrystalline Cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, cross-linked carboxymethyl cellulose sodium, crospolyvinylpyrrolidone, crosslinked carboxymethyl fecula sodium, dried starch or their mixture.
Some embodiments therein, chlorine promise of the present invention is for healthy dispersion tablet, wherein, described acidulant is a kind of in citric acid, lactic acid, acetic acid, ethanedioic acid, malonic acid, succinic acid, tartaric acid, adipic acid, malic acid, nicotinic acid, pectic acid, ascorbic acid, caffeic acid, fumaric acid, maleic acid, phosphoric acid solution or their mixture.
Some embodiments therein, chlorine promise of the present invention is for healthy dispersion tablet, wherein, described binding agent is a kind of in hypromellose, sodium carboxymethyl cellulose, starch, pregelatinized Starch, polyvidone, gelatin, Polyethylene Glycol, ethanol, water or their mixture.
Some embodiments therein, chlorine promise of the present invention is for healthy dispersion tablet, and wherein, described lubricant and fluidizer are a kind of of micropowder silica gel, magnesium stearate, silicon dioxide, Pulvis Talci, Polyethylene Glycol apoplexy due to endogenous wind or their mixture.
On the other hand, the present invention relates to a kind of chlorine promise for the preparation method of healthy dispersion tablet, it comprises the steps: that (1) sieve chlorine promise respectively for health and pharmaceutic adjuvant; Binding agent be dissolved in concentration be 85% or following alcoholic solution or aqueous solution in after, then the acidulant of recipe quantity is dissolved in the solution containing binding agent, obtain acid solution; (2) chlorine promise is mixed homogeneously with filler, disintegrating agent, fluidizer after replacing the made acid solution embedding of Kang Caiyong step (1), adds binding agent, mixes, and makes soft material; (3) soft material is crossed to 14～30 mesh sieves, 40～60 DEG C dry, 14～30 order granulate; (4) add lubricant, mix homogeneously; (5) tabletting, makes chlorine promise for healthy dispersion tablet.
Some embodiments therein, chlorine promise of the present invention, for the preparation method of healthy dispersion tablet, wherein, is that chlorine promise is passed through to fluid bed embedding for health and acid solution with acid solution embedding described in step (2), or chlorine promise is put into colloid mill for health together with acid solution and shear, drier.
Chlorine promise of the present invention is not passed through teaching material or other reference material gained for the prescription ratio of healthy dispersion tablet, but by the testing program gained conforming with the regulations in a large number, made dispersible tablet has carried out quality research, meets " Chinese Pharmacopoeia " 2010 editions two and make by oneself about dispersible tablet and other requirement of quality standard.In research, find the obvious existing conventional tablet of dissolution of technical solution of the present invention.
Compared with prior art, the present invention has following beneficial effect:
(1) the present invention makes tablet formulation by chlorine promise for health, and each drug component ratio is to be screened and obtained by repetition test, can significantly improve its bioavailability;
(2) the present invention granulates after adopting acidulant to process in chlorine promise is prepared for healthy dispersion tablet, greatly improves its bioavailability;
(3) tablet formulation that the present invention makes, compared with ordinary tablet, stripping is rapid, and disintegrative is good, and disintegrate completely in 1 minute absorbs soon, and bioavailability is high, stable in properties;
(4) tablet formulation that the present invention makes, does not use surface active agent solubilization in manufacturing process, reduce body is stimulated, and has reduced the untoward reaction of medicine, has increased patient's compliance.
Excipient of the present invention comprises, but be not limited to, ion-exchanger, aluminum, aluminium stearate, lecithin, serum albumin, as human albumin, buffer substance is as phosphate, glycine, sorbic acid, potassium sorbate, the partial glycerol ester admixture of saturated vegetable fatty acid, water, salt or electrolyte, as protamine sulfate, sodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salt, colloid silicon, magnesium trisilicate, polyvinylpyrrolidone, polyacrylate, wax, polyethylene-polyoxypropylene-blocking-up polymer, lanoline, sugar, as lactose, dextrose plus saccharose, starch is as corn starch and potato starch, the derivant of cellulose and it is as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate, natural gum powder, Fructus Hordei Germinatus, gelatin, Pulvis Talci, adjuvant is as cocoa butter and suppository wax, oily as Oleum Arachidis hypogaeae semen, Oleum Gossypii semen, safflower oil, Oleum Sesami, olive oil, Semen Maydis oil and Oleum Glycines, glycols compound, as propylene glycol and Polyethylene Glycol, esters is as ethyl oleate and ethyl laurate, agar, buffer agent is as magnesium hydroxide and aluminium hydroxide, alginic acid, pyrogen-free water, Deng oozing salt, Lin Ge (family name) solution, ethanol, phosphate buffer solution, and other nontoxic proper lubrication agent are as sodium laurylsulfate and magnesium stearate, coloring agent, releasing agent, coating dress material, sweeting agent, flavoring agent and spice, antiseptic and antioxidant.
Pharmaceutical composition of the present invention can also optionally contain one or more diluent.The example of diluent comprises mannitol, sorbitol, biphosphate calcium dihydrate, microcrystalline Cellulose and efflorescence cellulose.Preferred diluent is microcrystalline Cellulose.Microcrystalline Cellulose can be obtained from several suppliers, comprises Avicel PH101, Avicel PH102, Avicel PH103, Avicel PH105 and Avicel PH200 that FMC Corporation manufactures.
Pharmaceutical composition of the present invention can also optionally contain disintegrating agent.Disintegrating agent can be the one in several modified starches, modified cellulose polymer or polycarboxylic acids, such as crosslinked Carboxymethyl cellulose sodium, Explotab, polacrilin potassium and calcium carboxymethylcellulose (CMCCalcium).In one embodiment, disintegrating agent is croscarmellose sodium.Croscarmellose sodium NF type A obtains with trade name " Ac-di-sol " on market.
Pharmaceutical composition of the present invention can also optionally contain one or more surfactants or wetting agent.Surfactant can be anion, cation or neutral surface active agent.Anion surfactant comprises sodium lauryl sulfate, dodecyl sodium sulfate, oleyl sodium sulfate and the sodium laurate mixing with stearate and Talcum.Cationic surfactant comprises benzalkonium chloride and alkyl trimethyl ammonium bromide.Neutral surface active agent comprises glycerol list olein, polyoxyethylene sorbitan fatty acid ester, polyvinyl alcohol and anhydro sorbitol fat.The embodiment of wetting agent comprises poloxamer, polyoxyethylene alkyl ether, castor oil derivatives and polyoxyethylene 8 stearate fat.
The present invention can also optionally join antioxidant in preparation, thereby gives its chemical stability.Antioxidant is selected from the extract of a-tocopherol, Y-tocopherol, S-tocopherol, tocopherol enrichment natural origin, sodium or calcium salt, the Vitamin C acyl cetylate of L-AA and it, amass wealth by heavy taxation propyl propionate, amass wealth by heavy taxation misery ester, amass wealth by heavy taxation sour dodecyl ester, Yoshinox BHT (BHT) and butylated hydroxyanisol (BHA).In one embodiment, antioxidant is BHT or BHA.
The preferred dosage form of drug composition of the present invention is the tablet of preparing by compression method.Described tablet can carry out film with the mixture such as hydroxypropyl cellulose and hydroxypropyl emthylcellulose, contains titanium dioxide and/or other coloring agent, such as ferrum oxide, dyestuff and Se Dian in this mixture; The mixture of polyvinyl alcohol (PVA) and Polyethylene Glycol (PEG), contains titanium dioxide and/or other coloring agent, such as ferrum oxide, dyestuff and Se Dian; Or any other suitable instant-free coating agent.Coating provides taste masked and other stability to final tablet.What commercially available film provided for Colorcon is preparation mixture of powders
The present invention can also add sweeting agent and/or fumet.
Detailed description of the invention
Further explain the present invention below in conjunction with embodiment, but embodiment does not limit in any form to the present invention.
Embodiment 1
Chlorine promise is for health 8g
Lactose 300g
Crospolyvinylpyrrolidone 200g
Carboxymethylstach sodium 200g
Hydroxypropyl methylcellulose 7g
Micropowder silica gel 30g
Magnesium stearate 15g
Water 140g
95% ethanol 100g
Make 1000.
Preparation method:
Step 1: the chlorine promise of having pulverized is crossed respectively to 120 mesh sieves for health and pharmaceutic adjuvant, and hydroxypropyl methylcellulose first uses hot water swelling, is stirred to dissolving, then adds ethanol, makes concentration of alcohol reach 80%.
Step 2: press recipe quantity chlorine promise is replaced to health, lactose, polyvinylpolypyrrolidone, micropowder silica gel mix homogeneously, add the solution of hypromellose described in step 1 to make soft material.
Step 3: made soft material in step 2 is crossed to 18 mesh sieves and granulate, 50 DEG C dry, and moisture is 2.6%, 18 mesh sieve granulate.
Step 4: mix homogeneously with magnesium stearate making granule in step 3.
Step 5: semi-finished product detect, and determine sheet weight, tabletting, obtains chlorine promise for healthy dispersion tablet.
Embodiment 1 dispersible tablet smooth in appearance, dispersibility meets relevant regulations, but dissolution is not good.
Embodiment 2
Chlorine promise is for health 8g
Lactose 300g
Crospolyvinylpyrrolidone 67g
Carboxymethylstach sodium 200g
Hydroxypropyl methylcellulose 3.5g
Citric acid 100g
Micropowder silica gel 25g
Magnesium stearate 7.5g
Water 175
95% ethanol 114g
Make 1000.
Preparation method:
Step 1: the chlorine promise of having pulverized is crossed respectively to 120 mesh sieves for health and pharmaceutic adjuvant, and hydroxypropyl methylcellulose first uses hot water swelling, is stirred to dissolving, then adds ethanol, makes concentration of alcohol reach 80%.Separately get above-mentioned hydroxypropyl methylcellulose solution 3.5g, add 175g water, add citric acid mix homogeneously.
Step 2: the promise of recipe quantity chlorine is mixed homogeneously with recipe quantity lactose, crospolyvinylpyrrolidone, carboxymethylstach sodium, micropowder silica gel after the embedding of fluid bed acid solution with citric acid solution in step 1 for health, adds described in step 1, to remain hypromellose solution and make soft material.
Step 3: made soft material in step 2 is crossed to 16 mesh sieves and granulate, 50 DEG C dry, and moisture is 2.5%, 16 mesh sieve granulate.
Step 4: mix homogeneously with magnesium stearate making granule in step 3.
Step 5: semi-finished product detect, and determine sheet weight, tabletting, obtains chlorine promise for healthy dispersion tablet.
Embodiment 2 has added acidulant, has reduced the amount of disintegrating agent, and technique is optimized on the basis of embodiment 1, after first acidification, granulates again, finds dispersible tablet smooth in appearance, and dissolution is better, and dispersion effect is good, substantially again can disintegrate in 1 minute complete.
Embodiment 3
Chlorine promise is for health 8g
Crospolyvinylpyrrolidone 350g
Carboxymethylstach sodium 250g
Hydroxypropyl methylcellulose 3.5g
Citric acid 100g
Micropowder silica gel 15g
Magnesium stearate 7.5g
Water 166
95% ethanol 100g
Make 1000.
Preparation method is with embodiment 2.
Implementing 3 increases crospolyvinylpyrrolidone, carboxymethylstarch sodium content, and dispersible tablet dispersibility meets 2010 editions pharmacopeia requirements, and dissolution is better.
Embodiment 4
It is identical that embodiment 4 and embodiment 3 write out a prescription, and selects different acidify embedding modes, i.e. chlorine promise is put into colloid mill for health and acidulant solution and sheared, then spraying is dry.The indices of dispersible tablet and the embodiment 3 made dispersible tablet there was no significant difference of writing out a prescription.
Embodiment 5
Chlorine promise is for health 8g
Lactose 300g
Crospolyvinylpyrrolidone 150g
Carboxymethylstach sodium 100g
Starch 3.5g
Citric acid 100g
Acetic acid 100g
Micropowder silica gel 15g
Magnesium stearate 7.5g
Water 216g
Make 1000.
Preparation method:
Step 1: the chlorine promise of having pulverized is crossed respectively to 120 mesh sieves for health and pharmaceutic adjuvant, and starch adds water and makes starch slurry.Get the starch slurry 50g preparing, stir and add 180g water, then add citric acid, mix equal Uniform.
Step 2: the promise of recipe quantity chlorine is mixed homogeneously with recipe quantity lactose, crospolyvinylpyrrolidone, carboxymethylstach sodium, micropowder silica gel, acetic acid with part acid solution in step 1 for health after the embedding of fluid bed acid solution, adds remaining starch slurry described in step 1 to make soft material.
Step 3: made soft material in step 2 is crossed to 24 mesh sieves and granulate, 60 DEG C dry, and moisture is 2.4%, 24 mesh sieve granulate.
Step 4: mix homogeneously with magnesium stearate making granule in step 3.
Step 5: semi-finished product detect, and determine sheet weight, tabletting, obtains chlorine promise for healthy dispersion tablet.
Embodiment 5 starch in replace hydroxypropyl methylcellulose, all the other are constant, find that made dispersible tablet hardness declines to some extent at equal pressure condition lower sheeting, but also meet 2010 editions pharmacopeia dispersible tablet standards.
Embodiment 6
Chlorine promise is for health 8g
Starch 300g
Crospolyvinylpyrrolidone 200g
Carboxymethylstach sodium 50g
Hydroxypropyl methylcellulose 3g
Malic acid 100g
Micropowder silica gel 15g
Magnesium stearate 7g
Water 217g
95% ethanol 100g
Make 1000.
Preparation method is with embodiment 2.
Embodiment 6 changes filler, and replace lactose with starch, and malic acid is replaced to citric acid, the made dispersible tablet there was no significant difference of dispersible tablet and embodiment 3, dispersibility and dissolution are all better.
Embodiment 7
Chlorine promise is for health 8g
Icing Sugar 250g
Crospolyvinylpyrrolidone 150g
Carboxymethylstach sodium 150g
Hydroxypropyl methylcellulose 3.5g
Citric acid 100g
Micropowder silica gel 15g
Magnesium stearate 7.5g
Water 216g
95% ethanol 100g
Make 1000.
Preparation method is with implementing 2.
Embodiment 7 changes filler, replaces lactose with Icing Sugar, all the other with embodiment 3 together, the made dispersible tablet there was no significant difference of dispersible tablet and embodiment 3, dispersibility and dissolution are all better.
Embodiment 8
Chlorine promise is for health 8g
Starch 300g
Crospolyvinylpyrrolidone 100g
Carboxymethylstach sodium 150g
Hydroxypropyl methylcellulose 3.5g
Maleic acid 100g
Micropowder silica gel 15g
Magnesium stearate 7.5g
Water 216g
95% ethanol 100g
Make 1000.
Preparation method is with embodiment 7.
The made dispersible tablet smooth in appearance of embodiment 8, dissolution are good, and dispersibility is slightly poorer than adopting the dispersible tablet of citric acid, but adopts the dispersible tablet of oxalic acid to get well.
Biological test
(1) table 1 replaces healthy dispersion tablet and chlorine promise for chlorine promise and replaces the dissolution comparative result of health ordinary tablet (embodiment 1 gained dispersible tablet).
With reference to dissolution method (2010 editions two annex XC bis-methods of Chinese Pharmacopoeia).
The promise of table 1 chlorine is sold the comparison of ordinary tablet cumulative percentage dissolution for healthy dispersion tablet and market
As can be seen from Table 1, chlorine promise is obviously better than ordinary tablet for the dissolution in vitro of healthy dispersion tablet in 10-30min.
(2) chlorine promise is for healthy dispersion tablet assay
Measure with reference to high-efficient liquid phase technique (two annex VD of Chinese Pharmacopoeia version in 2010).
The promise of table 2 chlorine is for healthy dispersion tablet assay
| Batch | Chlorine promise is for healthy dispersion tablet content (%) |
| Batch 1 | 100.25 |
| Batches 2 | 100.38 |
| Batches 3 | 100.34 |
As can be seen from Table 2, chlorine promise is for the requirement that conforms with the regulations of the content of healthy dispersion tablet.
(3) chlorine promise is for the quality stability comparison of healthy dispersion tablet
Healthy dispersion tablet accelerated test is replaced in chlorine promise: replace healthy dispersion tablet to put under 2 DEG C of 40 DEG C of scholars of temperature, relative humidity 75% scholar's 5% condition the chlorine promise of blister package and place six months, outcome quality is stable, and indices is as shown in table 3.
The promise of table 3 chlorine is for six months accelerated test testing results of healthy dispersion tablet
| Inspection batch | Outward appearance | Disintegration | Dispersing uniformity | Dissolution % | Content % |
| Batch 1 | Yellow smooth | 38 | Conform with the regulations | 100.38 | 100.31 |
| Batches 2 | Yellow smooth | 40 | Conform with the regulations | 100.56 | 100.40 |
| Batches 3 | Yellow smooth | 39 | Conform with the regulations | 100.24 | 100.12 |
Claims (10)
1. chlorine promise is for a healthy dispersion tablet, and it comprises as follows according to the component of percetage by weight meter: chlorine promise is for health 0.5～16%, filler 10～50%, disintegrating agent 10～50%, acidulant 10～60%, binding agent 0.1～20%, lubricant and fluidizer 0.1～30%.
2. chlorine promise according to claim 1 is for healthy dispersion tablet, and it comprises as follows according to the component of percetage by weight meter: chlorine promise is for health 8%, filler 40%, disintegrating agent 37%, acidulant 10%, binding agent 2%, lubricant and fluidizer 3%.
3. lornoxicam dispersible tablet according to claim 1, the component that it comprises following percetage by weight meter:
Chlorine promise is for health 8g
Lactose 300g
Crospolyvinylpyrrolidone 67g
Carboxymethylstach sodium 200g
Hydroxypropyl methylcellulose 3.5g
Citric acid 100g
Micropowder silica gel 25g
Magnesium stearate 7.5g
Water 175
95% ethanol 114g
Make 1000.
4. chlorine promise according to claim 1 is for healthy dispersion tablet, and wherein, described filler is a kind of in starch, Icing Sugar, dextrin, lactose, microcrystalline Cellulose, mannitol, sorbitol or xylitol or their mixture.
5. chlorine promise according to claim 1 is for healthy dispersion tablet, wherein, described disintegrating agent is a kind of in microcrystalline Cellulose, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, cross-linked carboxymethyl cellulose sodium, crospolyvinylpyrrolidone, crosslinked carboxymethyl fecula sodium, dried starch or their mixture.
6. chlorine promise according to claim 1 is for healthy dispersion tablet, wherein, described acidulant is a kind of in citric acid, lactic acid, acetic acid, ethanedioic acid, malonic acid, succinic acid, tartaric acid, adipic acid, malic acid, nicotinic acid, pectic acid, ascorbic acid, caffeic acid, fumaric acid, maleic acid, phosphoric acid solution or their mixture.
7. chlorine promise according to claim 1 is for healthy dispersion tablet, and wherein, described binding agent is a kind of in hypromellose, sodium carboxymethyl cellulose, starch, pregelatinized Starch, polyvidone, gelatin, Polyethylene Glycol, ethanol, water or their mixture.
8. chlorine promise according to claim 1 is for healthy dispersion tablet, and wherein, described lubricant and fluidizer are a kind of of micropowder silica gel, magnesium stearate, silicon dioxide, Pulvis Talci, Polyethylene Glycol apoplexy due to endogenous wind or their mixture.
9. in claim 1-8, described in any one, chlorine promise is for the preparation method of healthy dispersion tablet, and it comprises the steps: that (1) sieve chlorine promise respectively for health and pharmaceutic adjuvant; Binding agent be dissolved in concentration be 85% or following alcoholic solution or aqueous solution in after, then the acidulant of recipe quantity is dissolved in the solution containing binding agent, obtain acid solution; (2) chlorine promise is mixed homogeneously with filler, disintegrating agent, fluidizer after replacing the made acid solution embedding of Kang Caiyong step (1), adds binding agent, mixes, and makes soft material; (3) soft material is crossed to 14～30 mesh sieves, 40～60 DEG C dry, 14～30 order granulate; (4) add lubricant, mix homogeneously; (5) tabletting, makes chlorine promise for healthy dispersion tablet.
10. chlorine promise according to claim 9 is for the preparation method of healthy dispersion tablet, wherein, described in step (2), be that chlorine promise is passed through to fluid bed embedding for health and acid solution with acid solution embedding, or chlorine promise put into colloid mill for health together with acid solution and shear, drier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410239718.6A CN103989648A (en) | 2014-05-30 | 2014-05-30 | Lomoxicam dispersible tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410239718.6A CN103989648A (en) | 2014-05-30 | 2014-05-30 | Lomoxicam dispersible tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103989648A true CN103989648A (en) | 2014-08-20 |
Family
ID=51304156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410239718.6A Pending CN103989648A (en) | 2014-05-30 | 2014-05-30 | Lomoxicam dispersible tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103989648A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1463702A (en) * | 2002-06-24 | 2003-12-31 | 北京上地新世纪生物医药研究所 | Analgetic pharmaceutical composition |
| CN102266300A (en) * | 2011-07-14 | 2011-12-07 | 广东药学院 | Gefitinib dispersible tablet and preparation method and application thereof |
-
2014
- 2014-05-30 CN CN201410239718.6A patent/CN103989648A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1463702A (en) * | 2002-06-24 | 2003-12-31 | 北京上地新世纪生物医药研究所 | Analgetic pharmaceutical composition |
| CN102266300A (en) * | 2011-07-14 | 2011-12-07 | 广东药学院 | Gefitinib dispersible tablet and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103908434B (en) | A kind of Sildenafil citrate tablets | |
| CN103768063B (en) | A kind of moxifloxacin hydrochloride medicinal composition and preparation method thereof | |
| CN103948560A (en) | Carbamazepine tablet and preparation method thereof | |
| EP3749286A1 (en) | A pharmaceutical composition comprising metamizole, drotaverine, and caffeine | |
| CN103877043A (en) | Sitgliptin phosphate dispersible tablet and preparation method thereof | |
| CN103893142A (en) | Onglyza dispersible tablet and preparation method thereof | |
| CN107334772A (en) | A kind of antiretroviral drugs composition | |
| CN104546779A (en) | Sildenafil citrate tablet with high medicine loading and preparation method thereof | |
| CN104739833A (en) | Compound double-layer tablet with Telmisartan and Rosuvastatin calcium and preparation method of compound double-layer tablet with Telmisartan and Rosuvastatin calcium | |
| CN103860496A (en) | Bazedoxifene acetate dispersing tablet and preparation method thereof | |
| CN103948553A (en) | Lamotrigine sustained release tablet and preparation method of lamotrigine sustained release tablet | |
| CN103784412A (en) | Icotinib hydrochloride dispersible tablet and preparation method thereof | |
| CN103860497A (en) | Meloxicam dispersible tablet and preparation method thereof | |
| CN103877046A (en) | Donepezil hydrochloride dispersible tablet and preparation method thereof | |
| CN103751140A (en) | Cabozantinib dispersible tablets and preparation method thereof | |
| CN103989648A (en) | Lomoxicam dispersible tablet and preparation method thereof | |
| EP3043872A1 (en) | Solid compositions based on minerals and orally disintegrating formulations containing the same. | |
| CN103877041B (en) | A kind of piroxicam dispersible tablet and preparation method thereof | |
| CN103536632A (en) | Self-microemulsifying brucea javanica oil oral granules and preparation method thereof | |
| CN103989647A (en) | Tenoxicam dispersible tablet and preparation method thereof | |
| CN102370629B (en) | Entecavir liquid capsule and preparation method thereof | |
| CN103860521A (en) | Icotinib hydrochloride capsule composition and preparation method thereof | |
| CN103948552A (en) | Oxcarbazepine controlled-release tablet and preparation method thereof | |
| CN103976966A (en) | Indomethacin tablet and preparation method thereof | |
| CN103860499A (en) | Methadone hydrochloride orally disintegrating tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140820 |
|
| RJ01 | Rejection of invention patent application after publication |